Evidence map›Paper›PMID 25560755›Full record

ArticleMolecular psychiatry2015

Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder.

D Arion, J P Corradi, S Tang, D Datta, F Boothe, A He, A M Cacace, R Zaczek, C F Albright, G Tseng and 1 more

Open access · greenAbstract read
In one paragraph

Article in Molecular psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 3 pooled it
16.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 3 syntheses or guidelines pooled it, 181 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Loss of function of the chromatin remodeling geneProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Mitochondrial Oxidative Phosphorylation System Dysfunction in Schizophrenia.International journal of molecular sciences · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

D ArionDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
J P CorradiBristol-Myers Squibb, Research Parkway, Wallingford, CT, USA.
S TangDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.
D DattaDepartment of Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA.
F BootheDepartment of Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA.
A HeBristol-Myers Squibb, Research Parkway, Wallingford, CT, USA.
A M CacaceBristol-Myers Squibb, Research Parkway, Wallingford, CT, USA.
R ZaczekBristol-Myers Squibb, Research Parkway, Wallingford, CT, USA.
C F AlbrightBristol-Myers Squibb, Research Parkway, Wallingford, CT, USA.
G TsengDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.
D A LewisDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
University of Pittsburgh · USBristol-Myers Squibb (United States) · US

Funding

Project 5: In vivo measurement of GABA transmission in healthy controls & subjectP50MH084053 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEWIS, DAVID A · 2008 to 2012
$11.5M
Statistics and Data Management CoreP50MH103204 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI OLSON, CARL ROGER · 2014 to 2018
$10.8M
SCHIZOPHRENIA AND CORTICAL DOPAMINE/GABA INTERACTIONSR01MH043784 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEWIS, DAVID A · 1988 to 2023
$7.2M
GABA Neurons and Cortical Circuitry in SchizophreniaR37MH043784 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEWIS, DAVID A · 2001 to 2010
$6.8M
NIMH NIH HHS MH043784NIMH NIH HHS MH084053NIMH NIH HHS MH103204NIMH NIH HHS P50 MH084053NIMH NIH HHS P50 MH103204NIMH NIH HHS R01 MH043784NIMH NIH HHS R37 MH043784
6 · The paper itself

Abstract

Schizophrenia is associated with alterations in working memory that reflect dysfunction of dorsolateral prefrontal cortex (DLPFC) circuitry. Working memory depends on the activity of excitatory pyramidal cells in DLPFC layer 3 and, to a lesser extent, in layer 5. Although many studies have profiled gene expression in DLPFC gray matter in schizophrenia, little is known about cell-type-specific transcript expression in these two populations of pyramidal cells. We hypothesized that interrogating gene expression, specifically in DLPFC layer 3 or 5 pyramidal cells, would reveal new and/or more robust schizophrenia-associated differences that would provide new insights into the nature of pyramidal cell dysfunction in the illness. We also sought to determine the impact of other variables, such as a diagnosis of schizoaffective disorder or medication use at the time of death, on the patterns of gene expression in pyramidal neurons. Individual pyramidal cells in DLPFC layers 3 or 5 were captured by laser microdissection from 36 subjects with schizophrenia or schizoaffective disorder and matched normal comparison subjects. The mRNA from cell collections was subjected to transcriptome profiling by microarray followed by quantitative PCR validation. Expression of genes involved in mitochondrial (MT) or ubiquitin-proteasome system (UPS) functions were markedly downregulated in the patient group (P-values for MT-related and UPS-related pathways were <10(-7) and <10(-5), respectively). MT-related gene alterations were more prominent in layer 3 pyramidal cells, whereas UPS-related gene alterations were more prominent in layer 5 pyramidal cells. Many of these alterations were not present, or found to a lesser degree, in samples of DLPFC gray matter from the same subjects, suggesting that they are pyramidal cell specific. Furthermore, these findings principally reflected alterations in the schizophrenia subjects were not present or present to a lesser degree in the schizoaffective disorder subjects (diagnosis of schizoaffective disorder was the most significant covariate, P<10(-6)) and were not attributable to factors frequently comorbid with schizophrenia. In summary, our findings reveal expression deficits in MT- and UPS-related genes specific to layer 3 and/or layer 5 pyramidal cells in the DLPFC of schizophrenia subjects. These cell type-specific transcriptome signatures are not characteristic of schizoaffective disorder, providing a potential molecular-cellular basis of differences in clinical phenotypes.

Indexed as

AdultAnalysis of VarianceAnimalsAntipsychotic AgentsFemaleGene Expression ProfilingGene Expression RegulationHumansLaser Capture MicrodissectionMacaca fascicularisMaleMiddle AgedMitochondrial ProteinsOligonucleotide Array Sequence AnalysisPrefrontal CortexPsychotic DisordersAntipsychotic AgentsMitochondrial ProteinsRNA, MessengerUbiquitin

Identifiers

PMID25560755
PMCPMC4492919
OpenAlexW1989747504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.